How pharma's arguments about price negotiations fall short; U.K. strikes deal to join major E.U. research program

Taking stock of the drug industry, from the lab to the medicine chest

September 7, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Why the drug industry's opaque warnings on price negotiations fall short Ever since Medicare was given power to negotiate some drug prices, the pharmaceutical industry has argued the move will hurt patients. By Ed Silverman STAT+ | In boon for scientists, U.K. strikes deal to join E.U. Horizon research program The U.K. has joined the E.U.'s Horizon research initiative, allowing British scientists to participate in the $100 billion program.  By Andrew Joseph What could fix cancer clinical trials' longstanding diversity problem? When clinical trials lack diversity, it's difficult to understand how findings apply to the populations underrepresented in the trial. By Deborah Balthazar Rachel Wisniewski for STAT Not yet free from heroin's grip, an 'honest, funny man' finds his way off the streets To the Prevention Point program in Philadelphia, needle exchange is just one of many social services for people with opioid use disorder. By Rachel Wisniewski

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser